| 摘要 |
<p>The present application discloses a compound, or enantiomers, stereoisomers,rotamers, tautomers, racemates or prodrug of said compound, or pharmaceuticallyacceptable salts, solvates or esters of said compound, or of said prodrug, saidcompound having the general structure shown in Formula 1: Chemical formula shouldbe inserted here as it appears on the abstract in paper form. or a pharmaceuticallyacceptable salt, solvate or ester thereof. Also disclosed is a method of treatingchemokine mediated diseases, such as, palliative therapy, curative therapy,prophylactic therapy of certain diseases and conditions such as inflammatorydiseases (non limiting example(s) include, psoriasis), autoimmune diseases(non limiting example(s) include, rheumatoid arthritis, multiple sclerosis),graft rejection (non limiting example(s) include, allograft rejection, zenograftrejection), infectious diseases (e.g , tuberculoid leprosy), fixed drug eruptions,cutaneous delayed type hypersensitivity responses, ophtha lmic inflammation,type I diabetes, viral meningitis and tumors using a compound of Formula 1.</p> |
